APRE - Aprea Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2019
12/30/2018
12/30/2017
Total Revenue
0
0
0
0
Operating Expenses
Research Development
20,951
20,951
14,195
13,393
Selling General and Administrative
8,594
8,594
2,295
2,460
Total Operating Expenses
29,544
29,544
16,489
15,852
Operating Income or Loss
-29,544
-29,544
-16,489
-15,852
Interest Expense
-
-
0
0
Total Other Income/Expenses Net
1,328
1,328
961
662
Income Before Tax
-28,060
-28,060
-15,528
-15,190
Income from Continuing Operations
-28,060
-28,060
-15,528
-15,190
Net Income
-28,060
-28,060
-15,528
-15,190
Net Income available to common shareholders
-28,060
-28,060
-15,528
-15,190
EBITDA
-
-29,544
-15,520
-15,182